Faculty profile

Josee-Lyne Ethier

ResearcherCancer Care and EpidemiologyQueen's University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.

Josee-Lyne Ethier

Researcher

Cancer Care and Epidemiology

Health Sciences

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2023.
Principal investigator on 3 research grants (3 CIHR), most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Endocrine Therapy Endometrial Cancer International Molecular Classification Non-Inferiority Phase Iii Quality Of Life Radiotherapy

Latest papers

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
Cancers · 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Nature communications · 2023
Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer.
Journal of cancer policy · 2023 · first author

All 11 publications

Latest funding

Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
CIHR · 2026 · Principal investigator
$1,575,898
Using a Liquid Biopsy to Optimize Metastatic Breast Cancer Treatment
CIHR · 2022 · Co-investigator
$891,226
Real-World Outcomes Associated with PARP Inhibitor Maintenance Therapy in Ovarian Cancer: A Population-Based Study
CIHR · 2022 · Nominated PI
$100,000

All 4 grants and awards

11 publications.

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.

Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X

Cancers2023

DOI: 10.3390/cancers15061823 PMID: 36980708

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S

Nature communications2023

DOI: 10.1038/s41467-023-37084-w PMID: 36922497

Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer.

Ethier JL, Kong W, MacKay HJ, McGee J, Booth CM

Journal of cancer policy2023First author

DOI: 10.1016/j.jcpo.2023.100421 PMID: 37030536

Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline

Hirte H, Poon R, Yao X, May T, Ethier J-L, Petz L, Speakman J, Elit L

Current Oncology20228 citations

DOI: 10.3390/curroncol29010022

State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.

Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, Zamarin D

JCO precision oncology2022First author

DOI: 10.1200/po.22.00355 PMID: 36240472

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Hirte H, Poon R, Yao X, May T, Ethier J-L, Petz L, Speakman J, Elit L

Critical Reviews in Oncology/Hematology202111 citations

DOI: 10.1016/j.critrevonc.2021.103324

Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.

Ethier JL, Desautels D, Robinson A, Amir E, Kong W, Booth CM

JAMA oncology2021First author

DOI: 10.1001/jamaoncol.2021.2140 PMID: 34236387

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.

Ethier JL, Anderson GM, Austin PC, Clemons M, Parulekar W, Shepherd L, Summers Trasiewicz L, Tu D, Amir E

European journal of cancer (Oxford, England : 1990)2021First author

DOI: 10.1016/j.ejca.2021.02.034 PMID: 33853037

The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions.

Srikanthan A, Ethier JL, Amir E

Journal of adolescent and young adult oncology2019

DOI: 10.1089/jayao.2019.0030 PMID: 31158039

Perceived Barriers to Goals of Care Discussions With Patients With Advanced Cancer and Their Families in the Ambulatory Setting

Ethier J-L, Paramsothy T, You JJ, Fowler R, Gandhi S

Journal of Palliative Care201877 citationsFirst author

DOI: 10.1177/0825859718762287

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2026

Subject: Prospective PhD student: Endocrine Therapy Dear Professor Ethier, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data." (2023), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial" (2026), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Josee-Lyne Ethier

Research

Latest papers

Latest funding

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer.

Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline

State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.

The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions.

Perceived Barriers to Goals of Care Discussions With Patients With Advanced Cancer and Their Families in the Ambulatory Setting

Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial

Using a Liquid Biopsy to Optimize Metastatic Breast Cancer Treatment

Real-World Outcomes Associated with PARP Inhibitor Maintenance Therapy in Ovarian Cancer: A Population-Based Study

Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study

Frequent collaborators

Eitan Amir

Stephanie Lheureux

Holger Hirte

Laurie Elit

Xiaomei Yao

Amirrtha Srikanthan

Tracy Stockley

Xuan Li

Lisa Wang

Andrew Robinson

Jacob McGee

Stephen Welch

Robert Fowler

Mark Clemons

Wendy Parulekar

John Joon-young You

Lucy Gilbert